Biodegradable polyurethane foam modified with 55% polyethyleneglycol as a local hemostatic agent, a pilot study.

Phase 2

• Conditions: Stolling van humaan bloed; coagulation; 10019190

• Registration Number: NL-OMON31951
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

patients who require at least 2 extractions in 1 session

Exclusion Criteria

Patients under 18 years and immune compromised patients.
Patients who use oral anticoagulant therapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study parameter is the degree of clotformation ( concentration<br /><br>thrombin) in polyurethane foam in comparison with the baseline values of the<br /><br>blood and the concentration thrombin in Willospon and Novacol. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>